
Dec 23 (Reuters) - A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
The individual died on December 14 after suffering a stroke followed by a brain hemorrhage, according to the European Haemophilia Consortium, a patient support group.
The patient was enrolled in a study that was testing Hympavzi in patients with hemophilia A or B with or without inhibitors.
"Pfizer, together with the trial investigator and the independent external Data Monitoring Committee, are actively gathering information to better understand the complex, multi-factorial circumstances surrounding this occurrence," the company said in a statement.
The therapy, a once-a-week injection, gained U.S. approval last year to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older by targeting blood-clotting proteins.
Pfizer does not anticipate any impact to safety for patients treated with the drug based on its current knowledge and the overall clinical data collected to date, the company said.
People with hemophilia have a defect in a gene that regulates the production of proteins called clotting factors, causing spontaneous and severe bleeding following injuries or surgery.
Earlier this year, Pfizer said it would halt global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
Beqvez, a one-time therapy, was approved in the U.S. for the treatment of adults with moderate to severe hemophilia B.
(Reporting by Sneha S K in Bengaluru; Editing by Anil D'Silva)
LATEST POSTS
- 1
Russian authorities threaten WhatsApp with total ban - 2
Islamic State group militants claim capture and execution of a Nigerian brigadier general - 3
Africa's energy giants eye long-term gains on Iran war disruption - 4
UK clothing inflation climbs as Middle East turmoil threatens wider price rises - 5
Traveling Alone: An Excursion of Self-Disclosure
Dozens killed as Angola flood death toll rises
Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds
Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
Fireball sightings are surging across the US — here's what's really going on
Experience Is standing by: 10 Pleasant Setting up camp Areas to
Vacation destinations in America
A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
Supportive Tips On Home loans For First-Time Home Purchasers
Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond












